nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—PTGS2—thyroid cancer	0.485	1	CbGaD
Sulindac—ALB—Vandetanib—thyroid cancer	0.0368	0.735	CbGbCtD
Sulindac—CYP1A2—Sorafenib—thyroid cancer	0.0133	0.265	CbGbCtD
Sulindac—AKR1B1—saliva-secreting gland—thyroid cancer	0.0058	0.107	CbGeAlD
Sulindac—MAPK3—neck—thyroid cancer	0.00539	0.099	CbGeAlD
Sulindac—AKR1B1—trachea—thyroid cancer	0.00447	0.0822	CbGeAlD
Sulindac—MAPK3—saliva-secreting gland—thyroid cancer	0.0042	0.0772	CbGeAlD
Sulindac—AKR1B1—thyroid gland—thyroid cancer	0.00354	0.065	CbGeAlD
Sulindac—MAPK3—trachea—thyroid cancer	0.00324	0.0596	CbGeAlD
Sulindac—AKR1B1—head—thyroid cancer	0.00314	0.0577	CbGeAlD
Sulindac—PPARD—thyroid gland—thyroid cancer	0.00278	0.0511	CbGeAlD
Sulindac—MAPK3—thyroid gland—thyroid cancer	0.00257	0.0471	CbGeAlD
Sulindac—PPARD—head—thyroid cancer	0.00247	0.0454	CbGeAlD
Sulindac—MAPK3—head—thyroid cancer	0.00228	0.0418	CbGeAlD
Sulindac—AKR1B1—lymph node—thyroid cancer	0.0022	0.0404	CbGeAlD
Sulindac—PPARD—lymph node—thyroid cancer	0.00173	0.0318	CbGeAlD
Sulindac—MAPK3—lymph node—thyroid cancer	0.00159	0.0293	CbGeAlD
Sulindac—CYP1A1—trachea—thyroid cancer	0.001	0.0184	CbGeAlD
Sulindac—PTGS1—trachea—thyroid cancer	0.000881	0.0162	CbGeAlD
Sulindac—PTGS2—trachea—thyroid cancer	0.000843	0.0155	CbGeAlD
Sulindac—CYP1A2—thyroid gland—thyroid cancer	0.000805	0.0148	CbGeAlD
Sulindac—CYP1A1—thyroid gland—thyroid cancer	0.000794	0.0146	CbGeAlD
Sulindac—ALB—lymph node—thyroid cancer	0.00076	0.014	CbGeAlD
Sulindac—Vaginal haemorrhage—Epirubicin—thyroid cancer	0.000705	0.00376	CcSEcCtD
Sulindac—CYP1A1—head—thyroid cancer	0.000704	0.0129	CbGeAlD
Sulindac—Neuritis—Epirubicin—thyroid cancer	0.000699	0.00373	CcSEcCtD
Sulindac—PTGS1—thyroid gland—thyroid cancer	0.000697	0.0128	CbGeAlD
Sulindac—Pleural effusion—Epirubicin—thyroid cancer	0.000681	0.00364	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00068	0.00363	CcSEcCtD
Sulindac—Insomnia—Vandetanib—thyroid cancer	0.000676	0.00361	CcSEcCtD
Sulindac—Paraesthesia—Vandetanib—thyroid cancer	0.000671	0.00358	CcSEcCtD
Sulindac—Erythema multiforme—Sorafenib—thyroid cancer	0.00067	0.00358	CcSEcCtD
Sulindac—Dyspnoea—Vandetanib—thyroid cancer	0.000666	0.00356	CcSEcCtD
Sulindac—Tinnitus—Sorafenib—thyroid cancer	0.000661	0.00353	CcSEcCtD
Sulindac—Flushing—Sorafenib—thyroid cancer	0.000658	0.00351	CcSEcCtD
Sulindac—Dyspepsia—Vandetanib—thyroid cancer	0.000657	0.00351	CcSEcCtD
Sulindac—Vaginal haemorrhage—Doxorubicin—thyroid cancer	0.000652	0.00348	CcSEcCtD
Sulindac—Decreased appetite—Vandetanib—thyroid cancer	0.000649	0.00347	CcSEcCtD
Sulindac—Neuritis—Doxorubicin—thyroid cancer	0.000647	0.00345	CcSEcCtD
Sulindac—Ageusia—Epirubicin—thyroid cancer	0.000644	0.00344	CcSEcCtD
Sulindac—Fatigue—Vandetanib—thyroid cancer	0.000644	0.00344	CcSEcCtD
Sulindac—Constipation—Vandetanib—thyroid cancer	0.000639	0.00341	CcSEcCtD
Sulindac—Arrhythmia—Sorafenib—thyroid cancer	0.000633	0.00338	CcSEcCtD
Sulindac—Pleural effusion—Doxorubicin—thyroid cancer	0.000631	0.00337	CcSEcCtD
Sulindac—Alopecia—Sorafenib—thyroid cancer	0.000627	0.00335	CcSEcCtD
Sulindac—PTGS1—head—thyroid cancer	0.000619	0.0114	CbGeAlD
Sulindac—Gastrointestinal pain—Vandetanib—thyroid cancer	0.000611	0.00326	CcSEcCtD
Sulindac—Dysgeusia—Sorafenib—thyroid cancer	0.000605	0.00323	CcSEcCtD
Sulindac—Ageusia—Doxorubicin—thyroid cancer	0.000596	0.00318	CcSEcCtD
Sulindac—PTGS2—head—thyroid cancer	0.000591	0.0109	CbGeAlD
Sulindac—Body temperature increased—Vandetanib—thyroid cancer	0.00059	0.00315	CcSEcCtD
Sulindac—Anaemia—Sorafenib—thyroid cancer	0.000571	0.00305	CcSEcCtD
Sulindac—Glossitis—Epirubicin—thyroid cancer	0.000566	0.00302	CcSEcCtD
Sulindac—Angioedema—Sorafenib—thyroid cancer	0.000564	0.00301	CcSEcCtD
Sulindac—Syncope—Sorafenib—thyroid cancer	0.000554	0.00296	CcSEcCtD
Sulindac—Leukopenia—Sorafenib—thyroid cancer	0.000553	0.00295	CcSEcCtD
Sulindac—Loss of consciousness—Sorafenib—thyroid cancer	0.000543	0.0029	CcSEcCtD
Sulindac—Asthenia—Vandetanib—thyroid cancer	0.000536	0.00286	CcSEcCtD
Sulindac—Hypertension—Sorafenib—thyroid cancer	0.000533	0.00285	CcSEcCtD
Sulindac—Pruritus—Vandetanib—thyroid cancer	0.000528	0.00282	CcSEcCtD
Sulindac—Myalgia—Sorafenib—thyroid cancer	0.000526	0.00281	CcSEcCtD
Sulindac—Arthralgia—Sorafenib—thyroid cancer	0.000526	0.00281	CcSEcCtD
Sulindac—Glossitis—Doxorubicin—thyroid cancer	0.000524	0.0028	CcSEcCtD
Sulindac—Hyperkalaemia—Epirubicin—thyroid cancer	0.000513	0.00274	CcSEcCtD
Sulindac—Diarrhoea—Vandetanib—thyroid cancer	0.000511	0.00273	CcSEcCtD
Sulindac—Anaphylactic shock—Sorafenib—thyroid cancer	0.000504	0.00269	CcSEcCtD
Sulindac—Colitis—Epirubicin—thyroid cancer	0.000501	0.00268	CcSEcCtD
Sulindac—Shock—Sorafenib—thyroid cancer	0.000496	0.00265	CcSEcCtD
Sulindac—Dizziness—Vandetanib—thyroid cancer	0.000494	0.00264	CcSEcCtD
Sulindac—Thrombocytopenia—Sorafenib—thyroid cancer	0.000493	0.00263	CcSEcCtD
Sulindac—CYP1A1—lymph node—thyroid cancer	0.000493	0.00906	CbGeAlD
Sulindac—Aplastic anaemia—Epirubicin—thyroid cancer	0.00049	0.00262	CcSEcCtD
Sulindac—Anorexia—Sorafenib—thyroid cancer	0.00048	0.00256	CcSEcCtD
Sulindac—Coma—Epirubicin—thyroid cancer	0.000477	0.00255	CcSEcCtD
Sulindac—Vomiting—Vandetanib—thyroid cancer	0.000475	0.00254	CcSEcCtD
Sulindac—Hyperkalaemia—Doxorubicin—thyroid cancer	0.000474	0.00253	CcSEcCtD
Sulindac—Ecchymosis—Epirubicin—thyroid cancer	0.000472	0.00252	CcSEcCtD
Sulindac—Rash—Vandetanib—thyroid cancer	0.000471	0.00251	CcSEcCtD
Sulindac—Dermatitis—Vandetanib—thyroid cancer	0.00047	0.00251	CcSEcCtD
Sulindac—Headache—Vandetanib—thyroid cancer	0.000468	0.0025	CcSEcCtD
Sulindac—Colitis—Doxorubicin—thyroid cancer	0.000464	0.00248	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000459	0.00245	CcSEcCtD
Sulindac—Aplastic anaemia—Doxorubicin—thyroid cancer	0.000453	0.00242	CcSEcCtD
Sulindac—Dyspnoea—Sorafenib—thyroid cancer	0.000449	0.0024	CcSEcCtD
Sulindac—Nausea—Vandetanib—thyroid cancer	0.000444	0.00237	CcSEcCtD
Sulindac—Dyspepsia—Sorafenib—thyroid cancer	0.000443	0.00237	CcSEcCtD
Sulindac—Coma—Doxorubicin—thyroid cancer	0.000441	0.00236	CcSEcCtD
Sulindac—Decreased appetite—Sorafenib—thyroid cancer	0.000438	0.00234	CcSEcCtD
Sulindac—Ecchymosis—Doxorubicin—thyroid cancer	0.000437	0.00233	CcSEcCtD
Sulindac—Fatigue—Sorafenib—thyroid cancer	0.000434	0.00232	CcSEcCtD
Sulindac—PTGS1—lymph node—thyroid cancer	0.000433	0.00796	CbGeAlD
Sulindac—Photosensitivity—Epirubicin—thyroid cancer	0.000431	0.0023	CcSEcCtD
Sulindac—Constipation—Sorafenib—thyroid cancer	0.000431	0.0023	CcSEcCtD
Sulindac—Vascular purpura—Epirubicin—thyroid cancer	0.000423	0.00226	CcSEcCtD
Sulindac—Hepatic failure—Epirubicin—thyroid cancer	0.000422	0.00225	CcSEcCtD
Sulindac—Cardiac failure congestive—Epirubicin—thyroid cancer	0.000418	0.00223	CcSEcCtD
Sulindac—PTGS2—lymph node—thyroid cancer	0.000414	0.0076	CbGeAlD
Sulindac—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000412	0.0022	CcSEcCtD
Sulindac—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.000401	0.00214	CcSEcCtD
Sulindac—Urticaria—Sorafenib—thyroid cancer	0.0004	0.00214	CcSEcCtD
Sulindac—Photosensitivity—Doxorubicin—thyroid cancer	0.000399	0.00213	CcSEcCtD
Sulindac—Body temperature increased—Sorafenib—thyroid cancer	0.000398	0.00213	CcSEcCtD
Sulindac—Renal impairment—Epirubicin—thyroid cancer	0.000398	0.00213	CcSEcCtD
Sulindac—Purpura—Epirubicin—thyroid cancer	0.000393	0.0021	CcSEcCtD
Sulindac—Vascular purpura—Doxorubicin—thyroid cancer	0.000392	0.00209	CcSEcCtD
Sulindac—Hepatic failure—Doxorubicin—thyroid cancer	0.00039	0.00208	CcSEcCtD
Sulindac—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.000387	0.00206	CcSEcCtD
Sulindac—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.000379	0.00202	CcSEcCtD
Sulindac—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.000371	0.00198	CcSEcCtD
Sulindac—Hypersensitivity—Sorafenib—thyroid cancer	0.000371	0.00198	CcSEcCtD
Sulindac—Renal impairment—Doxorubicin—thyroid cancer	0.000368	0.00197	CcSEcCtD
Sulindac—Purpura—Doxorubicin—thyroid cancer	0.000364	0.00194	CcSEcCtD
Sulindac—Asthenia—Sorafenib—thyroid cancer	0.000361	0.00193	CcSEcCtD
Sulindac—Pruritus—Sorafenib—thyroid cancer	0.000356	0.0019	CcSEcCtD
Sulindac—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.000351	0.00187	CcSEcCtD
Sulindac—Diarrhoea—Sorafenib—thyroid cancer	0.000345	0.00184	CcSEcCtD
Sulindac—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.000341	0.00182	CcSEcCtD
Sulindac—Gastritis—Epirubicin—thyroid cancer	0.000335	0.00179	CcSEcCtD
Sulindac—Muscular weakness—Epirubicin—thyroid cancer	0.000334	0.00178	CcSEcCtD
Sulindac—Dizziness—Sorafenib—thyroid cancer	0.000333	0.00178	CcSEcCtD
Sulindac—Eosinophilia—Epirubicin—thyroid cancer	0.000324	0.00173	CcSEcCtD
Sulindac—Pancreatitis—Epirubicin—thyroid cancer	0.000321	0.00171	CcSEcCtD
Sulindac—Vomiting—Sorafenib—thyroid cancer	0.00032	0.00171	CcSEcCtD
Sulindac—Rash—Sorafenib—thyroid cancer	0.000318	0.0017	CcSEcCtD
Sulindac—Dermatitis—Sorafenib—thyroid cancer	0.000317	0.00169	CcSEcCtD
Sulindac—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.000316	0.00169	CcSEcCtD
Sulindac—Headache—Sorafenib—thyroid cancer	0.000316	0.00169	CcSEcCtD
Sulindac—Pancytopenia—Epirubicin—thyroid cancer	0.000311	0.00166	CcSEcCtD
Sulindac—Gastritis—Doxorubicin—thyroid cancer	0.00031	0.00166	CcSEcCtD
Sulindac—Muscular weakness—Doxorubicin—thyroid cancer	0.000309	0.00165	CcSEcCtD
Sulindac—Dysuria—Epirubicin—thyroid cancer	0.000306	0.00163	CcSEcCtD
Sulindac—Neutropenia—Epirubicin—thyroid cancer	0.000306	0.00163	CcSEcCtD
Sulindac—Eosinophilia—Doxorubicin—thyroid cancer	0.0003	0.0016	CcSEcCtD
Sulindac—Nausea—Sorafenib—thyroid cancer	0.000299	0.0016	CcSEcCtD
Sulindac—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000299	0.0016	CcSEcCtD
Sulindac—Pancreatitis—Doxorubicin—thyroid cancer	0.000297	0.00159	CcSEcCtD
Sulindac—Hyperglycaemia—Epirubicin—thyroid cancer	0.000295	0.00158	CcSEcCtD
Sulindac—Pneumonia—Epirubicin—thyroid cancer	0.000294	0.00157	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000289	0.00155	CcSEcCtD
Sulindac—Pancytopenia—Doxorubicin—thyroid cancer	0.000288	0.00154	CcSEcCtD
Sulindac—Renal failure—Epirubicin—thyroid cancer	0.000287	0.00153	CcSEcCtD
Sulindac—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000286	0.00153	CcSEcCtD
Sulindac—Jaundice—Epirubicin—thyroid cancer	0.000285	0.00152	CcSEcCtD
Sulindac—Stomatitis—Epirubicin—thyroid cancer	0.000285	0.00152	CcSEcCtD
Sulindac—Conjunctivitis—Epirubicin—thyroid cancer	0.000284	0.00152	CcSEcCtD
Sulindac—Dysuria—Doxorubicin—thyroid cancer	0.000283	0.00151	CcSEcCtD
Sulindac—Neutropenia—Doxorubicin—thyroid cancer	0.000283	0.00151	CcSEcCtD
Sulindac—Sweating—Epirubicin—thyroid cancer	0.00028	0.00149	CcSEcCtD
Sulindac—Haematuria—Epirubicin—thyroid cancer	0.000278	0.00149	CcSEcCtD
Sulindac—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000277	0.00148	CcSEcCtD
Sulindac—Epistaxis—Epirubicin—thyroid cancer	0.000275	0.00147	CcSEcCtD
Sulindac—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000273	0.00146	CcSEcCtD
Sulindac—Agranulocytosis—Epirubicin—thyroid cancer	0.000272	0.00145	CcSEcCtD
Sulindac—Pneumonia—Doxorubicin—thyroid cancer	0.000272	0.00145	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000268	0.00143	CcSEcCtD
Sulindac—Renal failure—Doxorubicin—thyroid cancer	0.000266	0.00142	CcSEcCtD
Sulindac—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000265	0.00141	CcSEcCtD
Sulindac—Stomatitis—Doxorubicin—thyroid cancer	0.000263	0.00141	CcSEcCtD
Sulindac—Jaundice—Doxorubicin—thyroid cancer	0.000263	0.00141	CcSEcCtD
Sulindac—Conjunctivitis—Doxorubicin—thyroid cancer	0.000263	0.0014	CcSEcCtD
Sulindac—Hepatitis—Epirubicin—thyroid cancer	0.000262	0.0014	CcSEcCtD
Sulindac—Sweating—Doxorubicin—thyroid cancer	0.000259	0.00138	CcSEcCtD
Sulindac—Haematuria—Doxorubicin—thyroid cancer	0.000258	0.00138	CcSEcCtD
Sulindac—Epistaxis—Doxorubicin—thyroid cancer	0.000255	0.00136	CcSEcCtD
Sulindac—Visual impairment—Epirubicin—thyroid cancer	0.000253	0.00135	CcSEcCtD
Sulindac—Agranulocytosis—Doxorubicin—thyroid cancer	0.000252	0.00135	CcSEcCtD
Sulindac—Erythema multiforme—Epirubicin—thyroid cancer	0.000248	0.00132	CcSEcCtD
Sulindac—Tinnitus—Epirubicin—thyroid cancer	0.000244	0.0013	CcSEcCtD
Sulindac—Flushing—Epirubicin—thyroid cancer	0.000243	0.0013	CcSEcCtD
Sulindac—Hepatitis—Doxorubicin—thyroid cancer	0.000242	0.00129	CcSEcCtD
Sulindac—Chills—Epirubicin—thyroid cancer	0.000235	0.00126	CcSEcCtD
Sulindac—Arrhythmia—Epirubicin—thyroid cancer	0.000234	0.00125	CcSEcCtD
Sulindac—Visual impairment—Doxorubicin—thyroid cancer	0.000234	0.00125	CcSEcCtD
Sulindac—Alopecia—Epirubicin—thyroid cancer	0.000232	0.00124	CcSEcCtD
Sulindac—Erythema multiforme—Doxorubicin—thyroid cancer	0.000229	0.00122	CcSEcCtD
Sulindac—Tinnitus—Doxorubicin—thyroid cancer	0.000226	0.00121	CcSEcCtD
Sulindac—Flushing—Doxorubicin—thyroid cancer	0.000225	0.0012	CcSEcCtD
Sulindac—Flatulence—Epirubicin—thyroid cancer	0.000225	0.0012	CcSEcCtD
Sulindac—Tension—Epirubicin—thyroid cancer	0.000224	0.0012	CcSEcCtD
Sulindac—Dysgeusia—Epirubicin—thyroid cancer	0.000223	0.00119	CcSEcCtD
Sulindac—Nervousness—Epirubicin—thyroid cancer	0.000222	0.00118	CcSEcCtD
Sulindac—Chills—Doxorubicin—thyroid cancer	0.000218	0.00116	CcSEcCtD
Sulindac—Arrhythmia—Doxorubicin—thyroid cancer	0.000217	0.00116	CcSEcCtD
Sulindac—Vision blurred—Epirubicin—thyroid cancer	0.000215	0.00115	CcSEcCtD
Sulindac—Alopecia—Doxorubicin—thyroid cancer	0.000214	0.00114	CcSEcCtD
Sulindac—Ill-defined disorder—Epirubicin—thyroid cancer	0.000212	0.00113	CcSEcCtD
Sulindac—Anaemia—Epirubicin—thyroid cancer	0.000211	0.00113	CcSEcCtD
Sulindac—Flatulence—Doxorubicin—thyroid cancer	0.000208	0.00111	CcSEcCtD
Sulindac—Tension—Doxorubicin—thyroid cancer	0.000207	0.00111	CcSEcCtD
Sulindac—Dysgeusia—Doxorubicin—thyroid cancer	0.000207	0.0011	CcSEcCtD
Sulindac—Malaise—Epirubicin—thyroid cancer	0.000206	0.0011	CcSEcCtD
Sulindac—Nervousness—Doxorubicin—thyroid cancer	0.000205	0.00109	CcSEcCtD
Sulindac—Vertigo—Epirubicin—thyroid cancer	0.000205	0.00109	CcSEcCtD
Sulindac—Syncope—Epirubicin—thyroid cancer	0.000205	0.00109	CcSEcCtD
Sulindac—Leukopenia—Epirubicin—thyroid cancer	0.000204	0.00109	CcSEcCtD
Sulindac—Palpitations—Epirubicin—thyroid cancer	0.000202	0.00108	CcSEcCtD
Sulindac—Loss of consciousness—Epirubicin—thyroid cancer	0.000201	0.00107	CcSEcCtD
Sulindac—Vision blurred—Doxorubicin—thyroid cancer	0.000199	0.00106	CcSEcCtD
Sulindac—Convulsion—Epirubicin—thyroid cancer	0.000198	0.00106	CcSEcCtD
Sulindac—Hypertension—Epirubicin—thyroid cancer	0.000197	0.00105	CcSEcCtD
Sulindac—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000196	0.00105	CcSEcCtD
Sulindac—Anaemia—Doxorubicin—thyroid cancer	0.000195	0.00104	CcSEcCtD
Sulindac—Chest pain—Epirubicin—thyroid cancer	0.000194	0.00104	CcSEcCtD
Sulindac—Myalgia—Epirubicin—thyroid cancer	0.000194	0.00104	CcSEcCtD
Sulindac—Arthralgia—Epirubicin—thyroid cancer	0.000194	0.00104	CcSEcCtD
Sulindac—Discomfort—Epirubicin—thyroid cancer	0.000192	0.00102	CcSEcCtD
Sulindac—Malaise—Doxorubicin—thyroid cancer	0.00019	0.00102	CcSEcCtD
Sulindac—Vertigo—Doxorubicin—thyroid cancer	0.00019	0.00101	CcSEcCtD
Sulindac—Syncope—Doxorubicin—thyroid cancer	0.000189	0.00101	CcSEcCtD
Sulindac—Leukopenia—Doxorubicin—thyroid cancer	0.000189	0.00101	CcSEcCtD
Sulindac—Palpitations—Doxorubicin—thyroid cancer	0.000187	0.000996	CcSEcCtD
Sulindac—Oedema—Epirubicin—thyroid cancer	0.000186	0.000994	CcSEcCtD
Sulindac—Anaphylactic shock—Epirubicin—thyroid cancer	0.000186	0.000994	CcSEcCtD
Sulindac—Loss of consciousness—Doxorubicin—thyroid cancer	0.000186	0.000991	CcSEcCtD
Sulindac—Shock—Epirubicin—thyroid cancer	0.000183	0.000978	CcSEcCtD
Sulindac—Convulsion—Doxorubicin—thyroid cancer	0.000183	0.000977	CcSEcCtD
Sulindac—Thrombocytopenia—Epirubicin—thyroid cancer	0.000182	0.000973	CcSEcCtD
Sulindac—Hypertension—Doxorubicin—thyroid cancer	0.000182	0.000973	CcSEcCtD
Sulindac—Tachycardia—Epirubicin—thyroid cancer	0.000182	0.00097	CcSEcCtD
Sulindac—Hyperhidrosis—Epirubicin—thyroid cancer	0.00018	0.000961	CcSEcCtD
Sulindac—Arthralgia—Doxorubicin—thyroid cancer	0.00018	0.00096	CcSEcCtD
Sulindac—Chest pain—Doxorubicin—thyroid cancer	0.00018	0.00096	CcSEcCtD
Sulindac—Myalgia—Doxorubicin—thyroid cancer	0.00018	0.00096	CcSEcCtD
Sulindac—Discomfort—Doxorubicin—thyroid cancer	0.000178	0.000948	CcSEcCtD
Sulindac—Anorexia—Epirubicin—thyroid cancer	0.000177	0.000948	CcSEcCtD
Sulindac—Hypotension—Epirubicin—thyroid cancer	0.000174	0.000929	CcSEcCtD
Sulindac—Oedema—Doxorubicin—thyroid cancer	0.000172	0.00092	CcSEcCtD
Sulindac—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000172	0.00092	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00017	0.000906	CcSEcCtD
Sulindac—Shock—Doxorubicin—thyroid cancer	0.000169	0.000905	CcSEcCtD
Sulindac—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000169	0.000901	CcSEcCtD
Sulindac—Insomnia—Epirubicin—thyroid cancer	0.000168	0.000899	CcSEcCtD
Sulindac—Tachycardia—Doxorubicin—thyroid cancer	0.000168	0.000898	CcSEcCtD
Sulindac—Paraesthesia—Epirubicin—thyroid cancer	0.000167	0.000893	CcSEcCtD
Sulindac—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000167	0.000889	CcSEcCtD
Sulindac—Dyspnoea—Epirubicin—thyroid cancer	0.000166	0.000886	CcSEcCtD
Sulindac—Somnolence—Epirubicin—thyroid cancer	0.000166	0.000884	CcSEcCtD
Sulindac—Anorexia—Doxorubicin—thyroid cancer	0.000164	0.000877	CcSEcCtD
Sulindac—Dyspepsia—Epirubicin—thyroid cancer	0.000164	0.000875	CcSEcCtD
Sulindac—Decreased appetite—Epirubicin—thyroid cancer	0.000162	0.000864	CcSEcCtD
Sulindac—Hypotension—Doxorubicin—thyroid cancer	0.000161	0.00086	CcSEcCtD
Sulindac—Fatigue—Epirubicin—thyroid cancer	0.000161	0.000857	CcSEcCtD
Sulindac—Constipation—Epirubicin—thyroid cancer	0.000159	0.00085	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000157	0.000838	CcSEcCtD
Sulindac—Insomnia—Doxorubicin—thyroid cancer	0.000156	0.000832	CcSEcCtD
Sulindac—Paraesthesia—Doxorubicin—thyroid cancer	0.000155	0.000826	CcSEcCtD
Sulindac—Dyspnoea—Doxorubicin—thyroid cancer	0.000154	0.00082	CcSEcCtD
Sulindac—Feeling abnormal—Epirubicin—thyroid cancer	0.000153	0.000819	CcSEcCtD
Sulindac—Somnolence—Doxorubicin—thyroid cancer	0.000153	0.000818	CcSEcCtD
Sulindac—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000152	0.000813	CcSEcCtD
Sulindac—Dyspepsia—Doxorubicin—thyroid cancer	0.000152	0.00081	CcSEcCtD
Sulindac—Decreased appetite—Doxorubicin—thyroid cancer	0.00015	0.0008	CcSEcCtD
Sulindac—Fatigue—Doxorubicin—thyroid cancer	0.000149	0.000793	CcSEcCtD
Sulindac—Urticaria—Epirubicin—thyroid cancer	0.000148	0.00079	CcSEcCtD
Sulindac—Constipation—Doxorubicin—thyroid cancer	0.000147	0.000787	CcSEcCtD
Sulindac—Body temperature increased—Epirubicin—thyroid cancer	0.000147	0.000786	CcSEcCtD
Sulindac—Feeling abnormal—Doxorubicin—thyroid cancer	0.000142	0.000758	CcSEcCtD
Sulindac—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000141	0.000752	CcSEcCtD
Sulindac—Hypersensitivity—Epirubicin—thyroid cancer	0.000137	0.000733	CcSEcCtD
Sulindac—Urticaria—Doxorubicin—thyroid cancer	0.000137	0.000731	CcSEcCtD
Sulindac—Body temperature increased—Doxorubicin—thyroid cancer	0.000136	0.000727	CcSEcCtD
Sulindac—Asthenia—Epirubicin—thyroid cancer	0.000134	0.000713	CcSEcCtD
Sulindac—Pruritus—Epirubicin—thyroid cancer	0.000132	0.000703	CcSEcCtD
Sulindac—Diarrhoea—Epirubicin—thyroid cancer	0.000127	0.00068	CcSEcCtD
Sulindac—Hypersensitivity—Doxorubicin—thyroid cancer	0.000127	0.000678	CcSEcCtD
Sulindac—Asthenia—Doxorubicin—thyroid cancer	0.000124	0.00066	CcSEcCtD
Sulindac—Dizziness—Epirubicin—thyroid cancer	0.000123	0.000657	CcSEcCtD
Sulindac—Pruritus—Doxorubicin—thyroid cancer	0.000122	0.000651	CcSEcCtD
Sulindac—Vomiting—Epirubicin—thyroid cancer	0.000118	0.000632	CcSEcCtD
Sulindac—Diarrhoea—Doxorubicin—thyroid cancer	0.000118	0.000629	CcSEcCtD
Sulindac—Rash—Epirubicin—thyroid cancer	0.000117	0.000627	CcSEcCtD
Sulindac—Dermatitis—Epirubicin—thyroid cancer	0.000117	0.000626	CcSEcCtD
Sulindac—Headache—Epirubicin—thyroid cancer	0.000117	0.000623	CcSEcCtD
Sulindac—Dizziness—Doxorubicin—thyroid cancer	0.000114	0.000608	CcSEcCtD
Sulindac—Nausea—Epirubicin—thyroid cancer	0.000111	0.000591	CcSEcCtD
Sulindac—Vomiting—Doxorubicin—thyroid cancer	0.00011	0.000585	CcSEcCtD
Sulindac—Rash—Doxorubicin—thyroid cancer	0.000109	0.00058	CcSEcCtD
Sulindac—Dermatitis—Doxorubicin—thyroid cancer	0.000109	0.000579	CcSEcCtD
Sulindac—Headache—Doxorubicin—thyroid cancer	0.000108	0.000576	CcSEcCtD
Sulindac—Nausea—Doxorubicin—thyroid cancer	0.000102	0.000546	CcSEcCtD
Sulindac—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—thyroid cancer	5.86e-05	0.000262	CbGpPWpGaD
Sulindac—MAPK3—Disease—PRKAR1A—thyroid cancer	5.83e-05	0.000261	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—KRAS—thyroid cancer	5.83e-05	0.000261	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—KRAS—thyroid cancer	5.8e-05	0.000259	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PRKAR1A—thyroid cancer	5.79e-05	0.000259	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling of activated FGFR—HRAS—thyroid cancer	5.79e-05	0.000259	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB4—HRAS—thyroid cancer	5.69e-05	0.000255	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TCF7L1—thyroid cancer	5.67e-05	0.000253	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CHST14—thyroid cancer	5.66e-05	0.000253	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—TERT—thyroid cancer	5.64e-05	0.000252	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—BRAF—thyroid cancer	5.59e-05	0.00025	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—TP53—thyroid cancer	5.58e-05	0.00025	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	5.58e-05	0.00025	CbGpPWpGaD
Sulindac—MAPK3—Disease—MEN1—thyroid cancer	5.57e-05	0.000249	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—TP53—thyroid cancer	5.5e-05	0.000246	CbGpPWpGaD
Sulindac—ALB—Metabolism—NDUFA13—thyroid cancer	5.48e-05	0.000245	CbGpPWpGaD
Sulindac—MAPK3—Insulin Signaling—HRAS—thyroid cancer	5.47e-05	0.000244	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—SST—thyroid cancer	5.46e-05	0.000244	CbGpPWpGaD
Sulindac—PTGS2—C-MYB transcription factor network—HRAS—thyroid cancer	5.44e-05	0.000243	CbGpPWpGaD
Sulindac—MAPK3—Downstream signal transduction—HRAS—thyroid cancer	5.44e-05	0.000243	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR—HRAS—thyroid cancer	5.41e-05	0.000242	CbGpPWpGaD
Sulindac—MAPK3—Regulation of toll-like receptor signaling pathway—AKT1—thyroid cancer	5.4e-05	0.000241	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB2—HRAS—thyroid cancer	5.39e-05	0.000241	CbGpPWpGaD
Sulindac—MAPK3—DAP12 signaling—HRAS—thyroid cancer	5.36e-05	0.00024	CbGpPWpGaD
Sulindac—MAPK3—Signaling by SCF-KIT—AKT1—thyroid cancer	5.34e-05	0.000239	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—PTEN—thyroid cancer	5.26e-05	0.000235	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CALCA—thyroid cancer	5.26e-05	0.000235	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—KRAS—thyroid cancer	5.25e-05	0.000235	CbGpPWpGaD
Sulindac—MAPK3—BDNF signaling pathway—AKT1—thyroid cancer	5.25e-05	0.000235	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	5.25e-05	0.000235	CbGpPWpGaD
Sulindac—ALB—Metabolism—CHST14—thyroid cancer	5.16e-05	0.000231	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—HPGD—thyroid cancer	5.14e-05	0.00023	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—KRAS—thyroid cancer	5.12e-05	0.000229	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling of activated FGFR—AKT1—thyroid cancer	5.11e-05	0.000228	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—TPR—thyroid cancer	5.1e-05	0.000228	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—CP—thyroid cancer	5.1e-05	0.000228	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	5.08e-05	0.000227	CbGpPWpGaD
Sulindac—MAPK3—Cellular Senescence—TP53—thyroid cancer	5.07e-05	0.000227	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—HRAS—thyroid cancer	5.04e-05	0.000225	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—HRAS—thyroid cancer	5.04e-05	0.000225	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—HRAS—thyroid cancer	5.04e-05	0.000225	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB4—AKT1—thyroid cancer	5.03e-05	0.000225	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	5.01e-05	0.000224	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—HRAS—thyroid cancer	5e-05	0.000223	CbGpPWpGaD
Sulindac—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	4.99e-05	0.000223	CbGpPWpGaD
Sulindac—PPARD—Gene Expression—PPARG—thyroid cancer	4.96e-05	0.000222	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	4.96e-05	0.000222	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—PPARG—thyroid cancer	4.95e-05	0.000221	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—HRAS—thyroid cancer	4.95e-05	0.000221	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—HRAS—thyroid cancer	4.93e-05	0.00022	CbGpPWpGaD
Sulindac—MAPK3—Insulin Signaling—AKT1—thyroid cancer	4.83e-05	0.000216	CbGpPWpGaD
Sulindac—PTGS2—Disease—TCF7L1—thyroid cancer	4.81e-05	0.000215	CbGpPWpGaD
Sulindac—MAPK3—Downstream signal transduction—AKT1—thyroid cancer	4.8e-05	0.000215	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR—AKT1—thyroid cancer	4.78e-05	0.000214	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—NRAS—thyroid cancer	4.77e-05	0.000213	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CDK1—thyroid cancer	4.76e-05	0.000213	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB2—AKT1—thyroid cancer	4.75e-05	0.000213	CbGpPWpGaD
Sulindac—MAPK3—DAP12 signaling—AKT1—thyroid cancer	4.73e-05	0.000212	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—NRAS—thyroid cancer	4.69e-05	0.00021	CbGpPWpGaD
Sulindac—MAPK3—MAPK Signaling Pathway—AKT1—thyroid cancer	4.64e-05	0.000208	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—HPGD—thyroid cancer	4.56e-05	0.000204	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—MINPP1—thyroid cancer	4.51e-05	0.000202	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	4.48e-05	0.0002	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—HRAS—thyroid cancer	4.47e-05	0.0002	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—AKT1—thyroid cancer	4.45e-05	0.000199	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—AKT1—thyroid cancer	4.45e-05	0.000199	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—AKT1—thyroid cancer	4.45e-05	0.000199	CbGpPWpGaD
Sulindac—MAPK3—Disease—CALCA—thyroid cancer	4.43e-05	0.000198	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—AKT1—thyroid cancer	4.41e-05	0.000197	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—AKT1—thyroid cancer	4.37e-05	0.000196	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—AKT1—thyroid cancer	4.35e-05	0.000195	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—HRAS—thyroid cancer	4.35e-05	0.000195	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CDK1—thyroid cancer	4.35e-05	0.000194	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—TP53—thyroid cancer	4.34e-05	0.000194	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	4.32e-05	0.000193	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	4.32e-05	0.000193	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—NRAS—thyroid cancer	4.25e-05	0.00019	CbGpPWpGaD
Sulindac—PTGDR2—GPCR downstream signaling—AKT1—thyroid cancer	4.23e-05	0.000189	CbGpPWpGaD
Sulindac—AKR1B1—Metabolism—AKT1—thyroid cancer	4.21e-05	0.000188	CbGpPWpGaD
Sulindac—MAPK3—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	4.19e-05	0.000187	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IFNA2—thyroid cancer	4.18e-05	0.000187	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.17e-05	0.000186	CbGpPWpGaD
Sulindac—ALB—Metabolism—HPGD—thyroid cancer	4.16e-05	0.000186	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TSHR—thyroid cancer	4.15e-05	0.000185	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—KRAS—thyroid cancer	4.11e-05	0.000184	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PRKAR1A—thyroid cancer	4.08e-05	0.000182	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—CCND1—thyroid cancer	4.08e-05	0.000182	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—KRAS—thyroid cancer	4.04e-05	0.000181	CbGpPWpGaD
Sulindac—MAPK3—Disease—CDK1—thyroid cancer	4.01e-05	0.000179	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—RXRA—thyroid cancer	4.01e-05	0.000179	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—AKT1—thyroid cancer	3.94e-05	0.000176	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—PTEN—thyroid cancer	3.94e-05	0.000176	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MEN1—thyroid cancer	3.9e-05	0.000174	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PPARG—thyroid cancer	3.86e-05	0.000173	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—AKT1—thyroid cancer	3.84e-05	0.000172	CbGpPWpGaD
Sulindac—ALB—Hemostasis—IFNA2—thyroid cancer	3.84e-05	0.000172	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NDUFA13—thyroid cancer	3.84e-05	0.000172	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—TP53—thyroid cancer	3.83e-05	0.000171	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	3.82e-05	0.000171	CbGpPWpGaD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	3.73e-05	0.000167	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—TPR—thyroid cancer	3.72e-05	0.000166	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.7e-05	0.000165	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—KRAS—thyroid cancer	3.66e-05	0.000164	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PRKAR1A—thyroid cancer	3.66e-05	0.000163	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—CCND1—thyroid cancer	3.65e-05	0.000163	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CHST14—thyroid cancer	3.61e-05	0.000161	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PTCH1—thyroid cancer	3.53e-05	0.000158	CbGpPWpGaD
Sulindac—PTGS2—Disease—TPR—thyroid cancer	3.52e-05	0.000158	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—NRAS—thyroid cancer	3.51e-05	0.000157	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—HRAS—thyroid cancer	3.49e-05	0.000156	CbGpPWpGaD
Sulindac—MAPK3—Immune System—NRG1—thyroid cancer	3.49e-05	0.000156	CbGpPWpGaD
Sulindac—PTGS2—Disease—PRKAR1A—thyroid cancer	3.47e-05	0.000155	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—HRAS—thyroid cancer	3.43e-05	0.000154	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.37e-05	0.000151	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	3.32e-05	0.000148	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.31e-05	0.000148	CbGpPWpGaD
Sulindac—PTGS2—Disease—MEN1—thyroid cancer	3.31e-05	0.000148	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—CCND1—thyroid cancer	3.26e-05	0.000146	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SST—thyroid cancer	3.23e-05	0.000144	CbGpPWpGaD
Sulindac—MAPK3—Disease—NRG1—thyroid cancer	3.22e-05	0.000144	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—RXRA—thyroid cancer	3.21e-05	0.000143	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—HRAS—thyroid cancer	3.11e-05	0.000139	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CALCA—thyroid cancer	3.11e-05	0.000139	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PTGS2—thyroid cancer	3.04e-05	0.000136	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—AKT1—thyroid cancer	3.03e-05	0.000136	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—NRAS—thyroid cancer	3.03e-05	0.000136	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—KRAS—thyroid cancer	3.02e-05	0.000135	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—PTEN—thyroid cancer	3e-05	0.000134	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—NRAS—thyroid cancer	2.97e-05	0.000133	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—TPR—thyroid cancer	2.95e-05	0.000132	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	2.95e-05	0.000132	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—HPGD—thyroid cancer	2.91e-05	0.00013	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PRKAR1A—thyroid cancer	2.9e-05	0.00013	CbGpPWpGaD
Sulindac—MAPK3—Disease—TERT—thyroid cancer	2.89e-05	0.000129	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CDK1—thyroid cancer	2.81e-05	0.000126	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—SLC5A5—thyroid cancer	2.78e-05	0.000124	CbGpPWpGaD
Sulindac—MAPK3—Disease—HIF1A—thyroid cancer	2.77e-05	0.000124	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—TP53—thyroid cancer	2.69e-05	0.00012	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—NRAS—thyroid cancer	2.68e-05	0.00012	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PTEN—thyroid cancer	2.65e-05	0.000118	CbGpPWpGaD
Sulindac—PTGS2—Disease—CALCA—thyroid cancer	2.64e-05	0.000118	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.63e-05	0.000118	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—TPR—thyroid cancer	2.62e-05	0.000117	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—KRAS—thyroid cancer	2.61e-05	0.000117	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.61e-05	0.000117	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PRKAR1A—thyroid cancer	2.58e-05	0.000115	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—HRAS—thyroid cancer	2.57e-05	0.000115	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—KRAS—thyroid cancer	2.56e-05	0.000114	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—PPARG—thyroid cancer	2.53e-05	0.000113	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	2.49e-05	0.000111	CbGpPWpGaD
Sulindac—PTGS2—Disease—CDK1—thyroid cancer	2.39e-05	0.000107	CbGpPWpGaD
Sulindac—ALB—Metabolism—TPR—thyroid cancer	2.39e-05	0.000107	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.36e-05	0.000105	CbGpPWpGaD
Sulindac—ALB—Metabolism—PRKAR1A—thyroid cancer	2.35e-05	0.000105	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—RXRA—thyroid cancer	2.34e-05	0.000105	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.33e-05	0.000104	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—KRAS—thyroid cancer	2.3e-05	0.000103	CbGpPWpGaD
Sulindac—MAPK3—Disease—BRAF—thyroid cancer	2.29e-05	0.000102	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—TP53—thyroid cancer	2.28e-05	0.000102	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.27e-05	0.000102	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—AKT1—thyroid cancer	2.27e-05	0.000101	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NRG1—thyroid cancer	2.26e-05	0.000101	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—HRAS—thyroid cancer	2.22e-05	9.92e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—SLC5A5—thyroid cancer	2.21e-05	9.88e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—HRAS—thyroid cancer	2.18e-05	9.73e-05	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—TP53—thyroid cancer	2.15e-05	9.6e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.13e-05	9.52e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TERT—thyroid cancer	2.03e-05	9.06e-05	CbGpPWpGaD
Sulindac—PPARD—Gene Expression—AKT1—thyroid cancer	1.96e-05	8.77e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—SLC5A5—thyroid cancer	1.96e-05	8.76e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—HRAS—thyroid cancer	1.96e-05	8.76e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—AKT1—thyroid cancer	1.96e-05	8.76e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—HIF1A—thyroid cancer	1.94e-05	8.66e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—AKT1—thyroid cancer	1.92e-05	8.59e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—NRG1—thyroid cancer	1.92e-05	8.57e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—RXRA—thyroid cancer	1.86e-05	8.3e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PTGS2—thyroid cancer	1.85e-05	8.27e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.84e-05	8.21e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.8e-05	8.07e-05	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	1.79e-05	8.02e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—SLC5A5—thyroid cancer	1.79e-05	7.99e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PTEN—thyroid cancer	1.75e-05	7.82e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—AKT1—thyroid cancer	1.73e-05	7.73e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—TERT—thyroid cancer	1.72e-05	7.69e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—NRAS—thyroid cancer	1.71e-05	7.63e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.67e-05	7.49e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—TPR—thyroid cancer	1.67e-05	7.47e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—RXRA—thyroid cancer	1.65e-05	7.36e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—HIF1A—thyroid cancer	1.65e-05	7.36e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	1.64e-05	7.34e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PTEN—thyroid cancer	1.61e-05	7.22e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—BRAF—thyroid cancer	1.6e-05	7.17e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.6e-05	7.16e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—NRAS—thyroid cancer	1.56e-05	6.97e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—AKT1—thyroid cancer	1.53e-05	6.82e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—RXRA—thyroid cancer	1.5e-05	6.71e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.49e-05	6.66e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PPARG—thyroid cancer	1.48e-05	6.6e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—KRAS—thyroid cancer	1.47e-05	6.57e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.46e-05	6.53e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—NRAS—thyroid cancer	1.44e-05	6.44e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—NRAS—thyroid cancer	1.43e-05	6.4e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—BRAF—thyroid cancer	1.36e-05	6.09e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—KRAS—thyroid cancer	1.34e-05	6e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SLC5A5—thyroid cancer	1.25e-05	5.59e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—HRAS—thyroid cancer	1.25e-05	5.58e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—KRAS—thyroid cancer	1.24e-05	5.54e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—KRAS—thyroid cancer	1.23e-05	5.51e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PPARG—thyroid cancer	1.17e-05	5.24e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.17e-05	5.24e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCND1—thyroid cancer	1.17e-05	5.24e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PTGS2—thyroid cancer	1.16e-05	5.19e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HRAS—thyroid cancer	1.14e-05	5.1e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PTEN—thyroid cancer	1.13e-05	5.05e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—AKT1—thyroid cancer	1.1e-05	4.93e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TP53—thyroid cancer	1.09e-05	4.89e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—HRAS—thyroid cancer	1.05e-05	4.71e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—RXRA—thyroid cancer	1.05e-05	4.7e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—HRAS—thyroid cancer	1.05e-05	4.68e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PPARG—thyroid cancer	1.04e-05	4.65e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.02e-05	4.57e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PTEN—thyroid cancer	1.01e-05	4.53e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NRAS—thyroid cancer	1.01e-05	4.51e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—AKT1—thyroid cancer	1.01e-05	4.5e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—AKT1—thyroid cancer	1e-05	4.48e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PTEN—thyroid cancer	9.6e-06	4.29e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PPARG—thyroid cancer	9.48e-06	4.24e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—AKT1—thyroid cancer	9.3e-06	4.16e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—AKT1—thyroid cancer	9.24e-06	4.13e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KRAS—thyroid cancer	8.68e-06	3.88e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—NRAS—thyroid cancer	8.56e-06	3.83e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PTGS2—thyroid cancer	8.18e-06	3.66e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PTEN—thyroid cancer	8.04e-06	3.59e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TP53—thyroid cancer	7.71e-06	3.45e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PTGS2—thyroid cancer	7.46e-06	3.33e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—HRAS—thyroid cancer	7.38e-06	3.3e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—KRAS—thyroid cancer	7.37e-06	3.3e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PTEN—thyroid cancer	7.13e-06	3.19e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PPARG—thyroid cancer	6.63e-06	2.96e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—AKT1—thyroid cancer	6.51e-06	2.91e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PTEN—thyroid cancer	6.5e-06	2.91e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—HRAS—thyroid cancer	6.26e-06	2.8e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—AKT1—thyroid cancer	5.84e-06	2.61e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—AKT1—thyroid cancer	5.53e-06	2.47e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PTGS2—thyroid cancer	5.22e-06	2.33e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—AKT1—thyroid cancer	4.63e-06	2.07e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PTEN—thyroid cancer	4.55e-06	2.03e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—AKT1—thyroid cancer	4.11e-06	1.84e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—AKT1—thyroid cancer	3.75e-06	1.68e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—AKT1—thyroid cancer	2.62e-06	1.17e-05	CbGpPWpGaD
